Jeff Michalski, MD

Dr. Michalski is a prostate cancer specialist, Chair of the Theranostics sub-Committee for NRG, and the Vice Chair of the Department of Radiation Oncology at Washington University Medical School. He serves as the medical director of the Siteman Cancer Center’s Clinical Trial Office and has served as the Principal Investigator for the Radiation Therapy Oncology Group at Washington University. He earned his medical degree from the Medical College of Wisconsin in Milwaukee and completed his internship in internal medicine at Columbia-Presbyterian Medical Center in New York, and residency in radiation oncology at Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis. Dr. Michalski’s research interests include radiation dose escalation in the management of prostate cancer; precision radiation therapy to reduce toxicity in late neuro-cognitive effects in children with medulloblastoma; and assessment of quality of life in survivors of adult and childhood malignancies. He served as the Principal Investigator of the Advanced Technology Consortium (ATC) and coordinated Quality Assurance of radiation therapy trials in the cooperative group programs. As the leader of the RTOG ATIC, he established guidelines for participation of emerging technologies such as Intensity Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT) and Proton Beam Radiation Therapy (PBRT). He was instrumental in coordinating trials that involved advanced imaging, such as RTOG 0522 and stereotactic body radiation therapy, such as RTOG 0236. As the PI of the ATC, he coordinates quality assurance of clinical trials using PBRT for Massachusetts General Hospital, and MD Anderson Cancer Center. He served as Co-Principal Investigator on a joint contract with the Veteran's Administration Medical Centers and ASTRO to develop a system to provide continuous feedback on the progress, quality and safety of veterans' cancer therapy.